OPKO HEALTH, INC. (OPK) Form 8-K — Oct 15, 2026
OPKO Health entered into a definitive Asset Purchase Agreement on October 14, 2026 to sell BioReference Health's clinical and anatomic pathology laboratory business to Labcorp. Labcorp will pay $722 million in cash at closing, subject to revenue-based adjustments, plus up to $150 million in additional cash over up to ten years tied to 4Kscore prostate cancer test sales (15% of qualifying cash receipts above a threshold). Closing requires HSR antitrust clearance and customary conditions, with an outside date of April 14, 2027; Labcorp owes OPKO a $28.88 million termination fee if the deal fails on governmental approval grounds.
Key figures
- Deal Value Usd
- 722000000
- Earnout rate
- 15% of 4Kscore cash receipts over threshold per 12-month period
- Outside date
- April 14, 2027
- Earnout up to
- $150,000,000 over up to 10 years based on 4Kscore sales
- Escrow deposit
- 10% of Closing Purchase Price
- General rw cap
- 10% of Purchase Price
- Indemnification deductible
- 1% of Purchase Price
- Termination fee payable to seller
- $28,880,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.